MavriX Bio is a biotechnology company focused on developing innovative therapies for individuals with Angelman syndrome (AS), a genetic disorder with no currently approved treatments. Supported by the Foundation for Angelman Syndrome Therapeutics (FAST) and leveraging the expertise from the AS²Bio drug development accelerator, the company aims to be a pioneer in the field of gene therapy for AS.
The company's mission is encapsulated in its slogan: "Our mission is to bring life-changing therapies to individuals living with Angelman syndrome (AS)." MavriX Bio is advancing a novel AAV-based gene therapy, representing a potential first-of-its-kind treatment for this challenging condition. By focusing on translational science, the startup is committed to bridging the gap between research and clinical application.
Though specific details about founding date, headquarters, and recent investments are unavailable, MavriX Bio shows significant promise in the rare disease landscape. Its strategic partnerships and commitment to patient-centric innovation position it as a noteworthy contender in the biotech space.
